Tassos Gianakakos
2017
In 2017, Tassos Gianakakos earned a total compensation of $3.2M as President, Chief Executive Officer and Director at MyoKardia, a 191% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $297,205 |
|---|---|
| Option Awards | $2,406,603 |
| Salary | $505,450 |
| Other | $1,000 |
| Total | $3,210,258 |
Gianakakos received $2.4M in option awards, accounting for 75% of the total pay in 2017.
Gianakakos also received $297.2K in non-equity incentive plan, $505.5K in salary and $1K in other compensation.
Rankings
In 2017, Tassos Gianakakos' compensation ranked 3,336th out of 14,666 executives tracked by ExecPay. In other words, Gianakakos earned more than 77.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,336 out of 14,666 | 77th |
Division Manufacturing | 1,145 out of 5,772 | 80th |
Major group Chemicals And Allied Products | 313 out of 2,075 | 85th |
Industry group Drugs | 241 out of 1,731 | 86th |
Industry Pharmaceutical Preparations | 190 out of 1,333 | 86th |
Source: SEC filing on April 16, 2018.
Gianakakos' colleagues
We found three more compensation records of executives who worked with Tassos Gianakakos at MyoKardia in 2017.